Apr 25,2024

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

DarioHealth unveiled new research published in the Journal of Internet Medicine, indicating a notable reduction in blood glucose levels among users managing weight alongside diabetes with the Dario platform. This retrospective study of 1,932 Dario members over a year revealed significant improvements in blood glucose levels and BMI for those utilizing Dario's weight monitoring feature compared to those who did not. The study underscores the importance of integrated solutions for managing Type 2 diabetes and obesity, offering promising implications for enhancing patient outcomes. The research was conducted in collaboration with the School of Public Health at the University of Haifa.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 25,2024

Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

DarioHealth Corp. unveiled new research published in the Journal of Internet Medicine, indicating a notable reduction in blood glucose levels among users managing weight alongside diabetes with the Dario platform. This retrospective study of 1,932 Dario members over a year revealed significant improvements in blood glucose levels and BMI for those utilizing Dario's weight monitoring feature compared to those who did not. The study underscores the importance of integrated solutions for managing Type 2 diabetes and obesity, offering promising implications for enhancing patient outcomes. The research was conducted in collaboration with the School of Public Health at the University of Haifa.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 21,2024

Early outcomes of referrals to the English National Health Service Digital Weight Management Programme

The study evaluates the effectiveness of the English National Health Service (NHS) Digital Weight Management Programme, a national digital intervention for weight management. Between April 2021 and March 2022, 63,937 referrals were made, with 50% of participants taking up the 12-week program. Of those who completed the program, the mean weight change was -3.9 kg, with 31% achieving a weight loss of ≥5%. The intervention demonstrated equitable access across different demographic groups and showed significant weight reductions regardless of participants' socioeconomic status. The findings suggest that digitally delivered weight management interventions can be effective at achieving clinically meaningful weight loss at a population level, potentially offering benefits for public health. The inclusion of personal coaching was associated with higher engagement and completion rates.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 19,2024

Experimental AI predicts whether cancer drugs will work

Researchers in the US have developed an artificial intelligence tool that can predict how a patient will respond to cancer treatment, bringing the concept of personalised therapy a step closer to reality. Their AI platform, called PERCEPTION, focuses on the transcriptome – a collection of all the mRNAs expressed in a cell – and was trained on publicly available data taken from large-scale studies that screened drugs against cancer cell lines. Current approaches to matching patients to drugs rely on bulk sequencing of tumour DNA and RNA, which takes an average of all the cells in a tumour sample, according to the NCI. However, tumours can have many different cell types, and researchers believe these subpopulations may respond differently to specific drugs. That could explain why some patients do not respond to certain drugs or develop resistance to them.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 22,2024

Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial

This RCT research aimed to compare the effects of continuous glucose monitoring (CGM) versus blood glucose monitoring (BGM) over 12 months in adults with insulin-treated type 2 diabetes. The study, conducted at Steno Diabetes Center Copenhagen, Denmark, involved 76 participants with poorly controlled type 2 diabetes. Results showed that CGM use led to significantly greater improvements compared to BGM in several key areas. These included an increase in time spent in the target glucose range, a decrease in HbA1c levels, a reduction in total daily insulin dose, weight loss, and improvements in self-rated diabetes-related health, well-being, satisfaction, and health behavior.

CLINICAL STUDY

#bgm

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 08,2024

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit announces a new study published in European Radiology, demonstrating the effectiveness of Lunit INSIGHT MMG in reducing radiologists' workload while improving cancer detection rates. The study, conducted with researchers from multiple universities in Turkey, analyzed over 22,000 mammograms from a decade. Utilizing Lunit INSIGHT MMG, the AI solution identified a potential workload reduction of 70% and a 30.5% increase in cancer detection accuracy. The AI system also detected a substantial percentage of interval and missed cancers, with potential diagnostic time savings of nearly 30 months.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Apr 10,2024

Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

DarioHealth announced two new studies published in Journal of Internet Medicine (JMIR) including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens. The study results from RCT trial involved 303 teens engaged in a self-guided Digital Mental Health Intervention (DMHI) during a 12-week period. Participants in the DMHI group experienced significant improvements in perceived stress, brooding, and loneliness compared to the control group, highlighting the potential of digital stress management programs as viable alternatives to traditional in-person interventions. The second study investigated the impact of relaxation tools such as breathing exercises and Cognitive Behavioral Therapy-based videos, and evaluated on a group of 490 people engaged in Dario's digital behavioral health solution with moderate and higher levels of stress at the beginning of a 10-week period. The study reveals a significant reduction in stress levels among participants who engaged in both digital CBT-based videos and breathing exercises, demonstrating the effectiveness of digital relaxation tools in personalized behavioral health programs.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Mar 26,2024

Efficacy of a Digital Diabetes Logbook for People With Type 1, Type 2, and Gestational Diabetes: Results From a Multicenter, Open-Label, Parallel-Group, Randomized Controlled Trial

This randomized controlled trial with a 12-week follow-up was conducted in 41 study sites across Germany, and assessed the effectiveness of a digital diabetes diary in reducing diabetes distress. Participants were randomly assigned to use the mySugr PRO app or no app (control group). A total of 397 participants completed the trial (drop-out rate: 6.4%). Results showed a significant reduction in diabetes distress in the intervention group compared to the control group. The study suggests that the digital diary could improve mental health in individuals with type 1, type 2, and gestational diabetes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 31,2024

Comparative Effectiveness of Hybrid Closed-Loop Automated Insulin Delivery Systems Among Patients with Type 1 Diabetes

This retrospective clinical study compared outcomes of patients with type 1 diabetes using different hybrid closed-loop (HCL) systems in a real-world setting. The study included patients from an academic endocrinology practice who were new to any HCL system between January 1, 2018, and November 18, 2022. The outcomes assessed were the percentage of time spent in the target glucose range (TIR), percentage of time spent below the target range (TBR), and changes in HbA1c levels. Results showed that there were significant reductions in HbA1c levels with Tandem Control IQ (CIQ) and Omnipod 5 (OP5), but not with Medtronic 670G/770G (MT). TIR was similar across all three systems, but TBR was highest with MT. In conclusion, while all HCL systems showed improvements in certain outcomes, there were differences in TBR, with MT having the highest rates. The differences in the percentage of time in automated delivery likely explain variations in HbA1c changes but not in TBR between HCL systems.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 26,2024

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

Lunit announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for Cancer Research (AACR). The study focuses on the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma (HNSCC) patients. In this phase II randomized clinical trial, 48 HNSCC patients were enrolled, with 24 receiving preoperative durvalumab and 24 receiving a combination of durvalumab plus tremelimumab before surgical resection. The study findings revealed that patients treated with the combination of durvalumab and tremelimumab exhibited significantly better 4-year distant recurrence-free survival (DRFS) compared to those receiving durvalumab monotherapy. Additionally, Lunit SCOPE IO's AI analysis backed the remarkable shift in the tumor microenvironment towards an inflamed phenotype, characterized by increased immune activity within the tumor area, in patients receiving combination therapy. 

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY